Diplomat Pharmacy, Inc. (DPLO): Atheer A Kaddis , EVP of Sales & Strategic Align of Diplomat Pharmacy, Inc. sold 12,325 shares on May 2, 2016. The Insider selling transaction was reported by the company on May 2, 2016 to the Securities and Exchange Commission. The shares were sold at $30.17 per share for a total value of $371,878.53 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 18, 2016, Atheer A Kaddis (EVP of Sales & Strategic Align) sold 24,650 shares at $30.00 per share price.On Dec 8, 2015, Philip R Hagerman (Chairman and CEO) sold 2,300,000 shares at $33.60 per share price.Also, On Dec 2, 2015, Gary W Kadlec (President) sold 30,000 shares at $35.08 per share price.On Aug 27, 2015, Sean Whelan (Chief Financial Officer) sold 149,534 shares at $38.25 per share price.
Diplomat Pharmacy Inc: On Wednesday, Apr 27, 2016 heightened volatility was witnessed in Diplomat Pharmacy Inc which led to swings in the share price. The shares opened for trading at $31.18 and hit $32.92 on the upside , eventually ending the session at $32.86, with a gain of 5.02% or 1.57 points. The heightened volatility saw the trading volume jump to 6,06,203 shares. The 52-week high of the share price is $52.3324 and the company has a market cap of $2,121 M . The 52-week low of the share price is at $22.41.
Company has been under the radar of several Street Analysts.Diplomat Pharmacy Inc is Initiated by Avondale to Mkt Outperform and the brokerage firm has set the Price Target at $38. The Rating was issued on Apr 19, 2016.Diplomat Pharmacy Inc is Initiated by Credit Suisse to Neutral. The Rating was issued on Mar 16, 2016.Diplomat Pharmacy Inc is Downgraded by JP Morgan to Neutral. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Mar 1, 2016.Diplomat Pharmacy Inc is Downgraded by Mizuho to Neutral and the brokerage firm has set the Price Target at $30. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Mar 1, 2016.
Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.